MBBS, MD (General Medicine), DM (Hepatology)
Consultant - Hepatology & Liver Transplant Physician
Dr Sandeep Satsangi is trained at PGI Chandigarh, which is considered as one of the top medical institutes of the country.
He has been trained exclusively in the field of Hepato biliary Sciences and Liver Transplantation and has been exposed to a wide spectrum of liver disorders.
- Consultant – Department of Hepatology and Liver transplantation, Apollo Hospital, Bangalore, India.
- Consultant – Department of Hepatology and Liver transplantation, BGS Gleneagles Global Hospital, Bangalore, India (2017-2019).
- Senior Resident – Department of Hepatology, P.G.I Chandigarh (2014-2017).
- Complex Hepatobiliary conditions
- Non alcoholic fatty liver disease
- Alcoholic liver diseases
- Cirrhosis of liver
- Acute liver failure
- Liver Cancer
- Liver Transplantation
- Oral Paper presentation at ISGCON 2016 held at New Delhi. | ‘Monocyte HLA-DR expression, neutrophil oxidative burst capacity and cytokine analysis in patients with decompensated cirrhosis with and without acute-on chronic liver failure (ACLF)’ | Received FIRST prize in the plenary session for the best paper award.
- Oral paper presentation at APASL- SINGLE THEME CONFERENCE- HCV Infection and Disease & Recent Advances in Liver Disease – 2015 (New-Delhi) | ‘Oral treatment with sofosbuvir plus ribavirin is preferred over interferon based triple therapy in patients with chronic hepatitis C’
- Oral paper presentation at 3rd International Liver symposium – 2016 (New-Delhi) | ‘Transient elastography is inaccurate in assessing hepatic fibrosis in patients with end stage renal disease and chronic hepatitis C’- Selected in the Top 5 papers and awarded a prize.
- At AASLD 2016- Boston | ‘Monocyte HLA-DR expression, neutrophil oxidative burst capacity and cytokine analysis in patients with decompensated cirrhosis with and without acute-on chronic liver failure (ACLF)’
- At INASL – 2015 (New- Delhi) | ‘Small intestinal bacterial overgrowth and toll like receptor signaling in patients with nonalcoholic fatty liver disease’
- At INASL – 2016 (New-Delhi)
- Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis
- Surveillance regarding prevention and care of Hepatitis B Virus (HBV) positive patients amongst the nurses.
- At INASL 2018
- Khat related liver disease- An Under Recognized entity !
1) Decentralized Care with Generic Direct-Acting Antivirals in the Management of Chronic Hepatitis C in a Public Health Care Setting. J Hepatol. July 2019.
2) Satsangi S. Response to terlipressin in hepatorenal syndrome- Predict to prognosticate! Clin Gastroenterol Hepatol. Accepted manuscript Feb. 2018.
3) Satsangi S. Post-Paracentesis Hemoperitoneum – Time to Become More Careful! Liver Int. Accepted manuscript. Feb 2018
4) Satsangi S. To use entecavir, tenofovir disoproxil fumarate or tenofovir alafenamide. It’s all about choosing the right patient! Eur J Gastroenterol Hepatol. Accepted manuscript Feb. 2018
5) Satsangi S. Immune-tolerant chronic hepatitis B infection- Is the liver really tolerating? J Clin Exp Hepatol 2018. Accepted Manuscript
6) Satsangi S. Khat consumption induced chronic liver disease: is it all autoimmune?. J Liver Res Disord Ther. 2018;4(2):64.
7) Satsangi S, Mehta M, Duseja A, Taneja S, Dhiman RK, Chawla Y. Dual treatment with sofosbuvir plus ribavirin is as effective as triple therapy with pegylated interferon plus sofosbuvir plus ribavirin in predominant genotype 3 patients with chronic hepatitis C. J Gastroenterol Hepatol. 2016.
8) Mehta M, Satsangi S, Duseja A, et al. Can Alcoholic Liver Disease and Nonalcoholic Fatty Liver Disease Co-Exist? J Clin Exp Hepatol 2017.
9) Sakpal M, Satsangi S, Mehta M et al. Vitamin D supplementation in patients with Nonalcoholic Fatty Liver Disease – A Randomized Controlled Trial. J Gastroenterol Hepatol Open 2017
10) Satsangi S, Acharya V, Kini H, Anupama K. An unusual cause of lung mass in a young female. Lung India. 2014;31(2):188-90.
11) Satsangi S, Chawla YK. Viral hepatitis: Indian scenario. Med J Armed Forces India. 2016;72(3):204-10.
12) Dhiman RK, Satsangi S, Grover GS, Puri P. Tackling the burden of hepatitis C in Punjab, India. J Clin Exp Hepatol. 2016 Sep;6(3):224-232
13) Chronic hepatitis C : Suspect, Detect & Treat. Sandeep Satsangi, Yogesh. K Chawla.
(Association of physicians of India ‘Medicine update’ 2015)
14) Recent advances in the medical management of portal hypertesion. Sandeep Satsangi, Yogesh. K Chawla.
(Association of physicians of India ‘Medicine update’ 2016)
15) How will I manage CHC genotype-1 after introduction of Direct-Acting Antivirals. Sandeep Satsangi, Yogesh. K Chawla.
(Progress in Gastroenterology & Hepatology 2015)
16) Satsangi S, Gupta N. Rheumatologic Manifestations of Viral Hepatitis B and C. Hepatitis. 2015.
17) Satsangi S, Dhiman RK. Combating the wrath of viral hepatitis in India. Indian J Med Res. 2016 Jul; 144(1): 1–5.
18) Treatment of Hepatitis B in Indian subcontinent. Sandeep Satsangi, Yogesh. K Chawla. Indian College of Physicians Monograph 2017.
19) Acute-on chronic liver failure – The Newer Paradigm. Sandeep Satsangi, Yogesh. K Chawla. Indian College of Physicians Monograph 2017.
20) NASH: Do we really have an Effective Treatment? Sandeep Satsangi, Ajay Duseja.
(Association of physicians of India ‘Medicine update’ 2017)
21) Dhiman RK, Satsangi S. Autoimmune diseases of the liver. Indian J Med Res. 2017 Jan; 145(1): 151–153